Biocardia Common Stock Total Equity from 2010 to 2026
| BCDA Stock | USD 1.14 0.03 2.56% |
Common Stock Total Equity | First Reported 2000-03-31 | Previous Quarter 17 K | Current Value 20 K | Quarterly Volatility 137.3 K |
Check Biocardia financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biocardia's main balance sheet or income statement drivers, such as Depreciation And Amortization of 73.2 K, Interest Expense of 6.6 K or Selling General Administrative of 3.3 M, as well as many indicators such as Price To Sales Ratio of 231, Dividend Yield of 0.03 or PTB Ratio of 6.75. Biocardia financial statements analysis is a perfect complement when working with Biocardia Valuation or Volatility modules.
Biocardia | Common Stock Total Equity | Build AI portfolio with Biocardia Stock |
Analyzing Biocardia's Common Stock Total Equity over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Common Stock Total Equity has evolved provides context for assessing Biocardia's current valuation and future prospects.
Latest Biocardia's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Biocardia over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Biocardia's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biocardia's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Biocardia Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 106,688 | |
| Geometric Mean | 40,431 | |
| Coefficient Of Variation | 125.32 | |
| Mean Deviation | 113,867 | |
| Median | 18,400 | |
| Standard Deviation | 133,705 | |
| Sample Variance | 17.9B | |
| Range | 456.2K | |
| R-Value | (0.57) | |
| Mean Square Error | 12.9B | |
| R-Squared | 0.32 | |
| Significance | 0.02 | |
| Slope | (15,007) | |
| Total Sum of Squares | 286B |
Biocardia Common Stock Total Equity History
About Biocardia Financial Statements
Biocardia stakeholders use historical fundamental indicators, such as Biocardia's Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Biocardia investors may analyze each financial statement separately, they are all interrelated. For example, changes in Biocardia's assets and liabilities are reflected in the revenues and expenses on Biocardia's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Biocardia. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 18.4 K | 17.5 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out the analysis of Biocardia Correlation against competitors. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. Projected growth potential of Biocardia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Biocardia assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Biocardia requires distinguishing between market price and book value, where the latter reflects Biocardia's accounting equity. The concept of intrinsic value - what Biocardia's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Biocardia's price substantially above or below its fundamental value.
It's important to distinguish between Biocardia's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biocardia should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biocardia's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.